Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
2024年4月26日 - 5:05AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company pioneering the use of gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that the
company will present the 26-week landmark interim analysis from its
ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec)
for the treatment of wet age-related macular degeneration (wet AMD)
at the American Society of Retina Specialists (ASRS) Annual
Scientific Meeting being held in Stockholm, Sweden from July 17 -
20, 2024.
ASRS Annual Scientific Meeting Presentation
Information
Title: Ixoberogene
Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD:
First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA
Study
Date / Time:
Wednesday, July 17th, 2024 at 8:45am CEST
Session: Wet AMD
Symposium 1
Presenter: Charles
C. Wykoff, MD, PhD, FASRS, Director of Research, Retina Consultants
of Texas; Professor of Clinical Ophthalmology, Blanton Eye
Institute, Houston Methodist Hospital
The presentation will be available on the News and Publications
section of Adverum’s website shortly after the presentation.
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage
company that aims to establish gene therapy as a new standard of
care for highly prevalent ocular diseases with the aspiration of
developing functional cures to restore vision and prevent
blindness. Leveraging the capabilities of its proprietary
intravitreal (IVT) platform, Adverum is developing durable,
single-administration therapies, designed to be delivered in
physicians’ offices, to eliminate the need for frequent ocular
injections to treat these diseases. Adverum is evaluating its novel
gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly
referred to as ADVM-022), as a one-time, IVT injection for patients
with neovascular or wet age-related macular degeneration.
Additionally, by overcoming the challenges associated with current
treatment paradigms for debilitating ocular diseases, Adverum
aspires to transform the standard of care, preserve vision, and
create a profound societal impact around the globe. For more
information, please visit www.adverum.com.
Forward-looking Statements
Statements contained in this press release and any accompanying
presentation regarding matters, events, statistics, or clinical or
financial results that may occur in the future are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements regarding plans and milestones related to Adverum’s
product candidates, clinical studies and trials, the therapeutic
and commercial potential of Adverum’s product candidates and the
sufficiency of Adverum’s resources to fund lead programs, all of
which are based on certain assumptions made by Adverum on current
conditions, expected future developments and other factors Adverum
believes are appropriate under the circumstances. Adverum may not
consummate any of these plans or these product, clinical
development, process development goals in a timely manner, or at
all, or otherwise carry out the intentions or meet the expectations
or projections disclosed in its forward-looking statements, and you
should not place undue reliance on these forward-looking
statements. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, the risk that Adverum’s resources will
not be sufficient for Adverum to conduct or continue planned
development programs and planned clinical trials, the risk that
preliminary or interim data from Adverum’s clinical trials may
change as more patient data become available, the risk of a delay
in the enrollment of patients in Adverum’s clinical studies or in
the manufacturing of products to be used in such clinical studies,
risks and uncertainties inherent in the product development and the
regulatory approval process, the risk that Adverum will not be able
to successfully develop, manufacture, or commercialize any of its
product candidates and the risk that Adverum will be delayed in
receiving or fail to receive required regulatory approvals.
Additional risks and uncertainties facing Adverum are set forth
under the caption “Risk Factors” and elsewhere in Adverum’s
Securities and Exchange Commission (SEC) filings and reports,
including Adverum’s most recent Annual Report on Form 10-K for the
year ended December 31, 2023 filed with the SEC on March 18, 2024
and in our Quarterly Reports on Form 10-Q for the quarterly periods
ended subsequent to our filing such Annual Report on Form 10-K, as
well as any amendments thereto reflected in subsequent filings with
the SEC. All forward-looking statements contained in this document
speak only as of the date on which they were made. Adverum
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as required by law.
Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
過去 株価チャート
から 5 2024 まで 6 2024
Adverum Biotechnologies (NASDAQ:ADVM)
過去 株価チャート
から 6 2023 まで 6 2024